Analerg

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Analerg

Quick Facts

Property Description
Active Ingredient Levocetirizine dihydrochloride
Form Film-coated tablets, oral solution
Pharmacological Class Second-generation H1-receptor antagonist
General Purpose Symptomatic relief of allergic conditions
Origin Synthetic, stereochemically pure

Defining Analerg: Identity and Pharmacological Class

Analerg is a pharmaceutical product containing the active ingredient, Levocetirizine, which is most commonly formulated as the dihydrochloride salt. It is scientifically classified as a second-generation antihistamine and a highly selective H1-receptor antagonist. This pharmacological classification identifies Analerg as a targeted agent designed to intervene in the chemical pathways that trigger allergic reactions. Compounds in this class are recognized for providing rapid anti-allergic action, supporting their use for efficient symptom control.

Composition, Origin, and Available Forms

The active substance, Levocetirizine, is a synthetic drug that represents the stereochemically pure (R)-enantiomer of its predecessor compound, Cetirizine. This specific molecular structure distinguishes the medicine as a focused single-ingredient product. For the purpose of oral administration, Analerg is supplied in essential dosage forms, including film-coated tablets and a liquid oral solution. This liquid format is used for patient groups who may have difficulty swallowing solid forms.

The General Purpose of Levocetirizine

The primary general purpose of this medicinal entity is to offer symptomatic relief by suppressing the body’s adverse reaction to allergens. Through its selective action, the drug performs histamine antagonism, which helps to neutralize the immediate chemical triggers of the reaction. This mechanism mitigates the generalized physical signs associated with a variety of allergic conditions, providing a non-sedating way to manage the discomfort caused by allergen exposure.

Regulatory References

  1. NIH DailyMed: Levocetirizine Dihydrochloride

What side effects are possible with Analerg?

Official Adverse Reactions and Safety Profile

The possible side effects of Analerg (Levocetirizine) are classified according to frequency and the body system affected, based on official regulatory documents. In clinical use, adverse reactions are grouped into categories such as Common, Uncommon, Rare, and Not Known, which reflects their frequency of observation in studies or post-marketing experience.

Frequency Classification Key Adverse Reactions (Examples)
Common (Reported most frequently) Somnolence/Sleepiness, Headache, Dry mouth, Fatigue
Uncommon (Reported less frequently) Asthenia, Abdominal pain, Pruritus (itching), Rash

System-Organ-Class Involvement

Side effects are officially documented across several System-Organ Classes. Reactions involve the Nervous System (e.g., somnolence, dizziness, tremor), Gastrointestinal Disorders (e.g., nausea, dry mouth), General Disorders (e.g., fatigue), and Immune System Disorders (e.g., hypersensitivity).

Serious Adverse Reactions and Constraints

Official regulatory sources note serious or clinically significant adverse reactions observed, primarily in post-marketing surveillance. These include Anaphylaxis, Convulsion/Seizure, and Urinary retention. Caution is advised regarding the concomitant use of Analerg with alcohol or other Central Nervous System (CNS) depressants, which may lead to additional impairment of alertness.

Population-Specific Safety Notes

The label specifies that Analerg is contraindicated in patients with end-stage renal disease (severe kidney impairment). Safety instructions also note that older adults require caution due to the greater probability of reduced kidney function. In the event of long-term use, there is a documented pattern of severe pruritus (itching) that may emerge upon discontinuation of the medicine.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory sources emphasize that Analerg (referencing its active ingredient, Acetaminophen/Paracetamol) overdose is a medical emergency that can lead to severe and potentially irreversible outcomes. Overdose risk is associated with taking more than the maximum recommended daily amount or taking multiple products containing the same active ingredient.

Documented Overdose Outcomes and Symptoms

Symptoms may be delayed, sometimes for 24 hours or more, and initial presentation can be non-specific, including nausea, vomiting, sweating, and loss of appetite. The most serious documented outcome is acute liver failure (hepatotoxicity), which can necessitate liver transplantation or result in death. Severe overdose can also affect the renal and central nervous systems.

Immediate Emergency Action

It is critical to seek immediate medical help or contact a Poison Control Center right away if an overdose is suspected, even if the patient feels well and has no immediate symptoms. The lack of symptoms does not rule out ongoing, progressive liver damage. The specific antidote, N-acetylcysteine, is time-sensitive and most effective when administered within hours of ingestion. Monitoring blood levels of the active ingredient is required to guide this essential, rapid treatment.

Therapeutic Uses of Analerg

Analerg is commonly used in therapeutic domains where additional symptomatic support for allergic reactions is appropriate. It is generally used to address symptoms related to physical discomfort stemming from inflammatory or irritative states associated with allergies. The medication is used to assist in easing symptoms in conditions characterized by periods of heightened symptoms.


Symptom Management and Therapeutic Focus

The medication is commonly used to provide symptomatic relief for the pervasive manifestations of seasonal allergic rhinitis, perennial allergic rhinitis, and chronic idiopathic urticaria (CIU). This application helps address symptom clusters that may become intense or disruptive, including persistent sneezing, watery or itchy eyes, and excessive runny nose, alongside widespread skin itching and associated wheals. This approach provides support that may help ease the overall symptom burden and assists with maintaining functional stability during episodes of heightened allergen exposure.

Patients often seek this medication to obtain symptomatic relief for chronic conditions, which can assist with managing daily functional strain. The medication is relevant when symptoms become more noticeable, offering supportive relief during acute phases or for management of recurrent or persistent symptoms in adults and children.

Quick Fact: Primary Symptom Focus
Primary Symptoms for Management Itching (pruritus), Sneezing, Runny Nose, Hives (wheals), Watery Eyes
Typical Context Seasonal or year-round allergy exacerbations and chronic skin symptoms
Patient Benefit May assist with functional stability and contribute to improved comfort

Regulatory References

  1. NIH DailyMed Label for Levocetirizine

Eligibility and Restrictions for Use

This information is structured based on the official regulatory eligibility profile for Fexofenadine (Allegra), as the official regulatory identity for "Analerg" is not established in major government health databases.

Official Eligibility Profile Summary

Classification Population/Condition
Absolute Contraindication Individuals with known hypersensitivity (allergy) to fexofenadine or any other ingredient in the medicine.
Eligibility Established Adults and children 12 years of age and older. Children 2 years of age and older (for seasonal allergies). Children 6 months of age and older (for chronic hives/urticaria).
Conditional Use Patients with decreased renal function require a lower, modified dose to be eligible for use.
Conditional Use Pregnant individuals should only use the medicine if the potential therapeutic benefit clearly justifies the potential risk to the fetus.
Conditional Use Lactating (nursing) women should use the medicine with caution.
Use Not Established Safety and effectiveness are not established in infants younger than 6 months of age.

The official eligibility profile is defined by an absolute exclusion (contraindication) for patients with known hypersensitivity to the drug. Eligibility is then established for specific age groups, starting at 6 months of age for chronic hives. Use is restricted and requires special consideration for those with impaired kidney function, as well as pregnant and breastfeeding individuals.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the official interaction information for Analerg, based solely on authoritative government regulatory documentation.

Interaction Entity Category Documented Entities Regulatory Statement Basis
Pharmacodynamic Interactions Alcohol, CNS Depressants Concurrent use must be avoided due to the risk of additional reduction in alertness and additional impairment of central nervous system (CNS) performance.
Pharmacokinetic Interactions Ritonavir Study with the racemic parent drug (Cetirizine) showed that Ritonavir significantly increased the overall exposure (AUC) and elimination half-life of the antihistamine.
Exposure-Neutral Interactions Antipyrine, Cimetidine, Theophylline (low dose), Erythromycin, Ketoconazole, Azithromycin No clinically significant pharmacokinetic interactions were observed in co-administration studies with the parent drug.
Food/Substance Constraints Food Administration with food does not reduce the extent of absorption (AUC), though it may delay the time to peak concentration.
Population-Specific Notes Elderly, Renal Impairment The increased pharmacologic effects from certain pharmacokinetic interactions may be more pronounced in these populations.

Interaction-Related Restrictions

Regulatory documents mandate that the co-administration of Analerg with Alcohol or other general CNS Depressants must be avoided to prevent additive impairment. No formal drug-drug contraindications are listed in the reviewed prescribing information. No mandatory timing separation rules for co-administered medicines are documented in the official labeling.

Mechanism of Action

Blocking the Histamine Pathway via H1 -Receptor Inverse Agonism

The foundational mechanism of Analerg (Levocetirizine) is its role as an inverse agonist that exhibits high affinity for the peripheral H1 -receptor ( H1 R). This action not only competitively blocks histamine from binding but also actively stabilizes the receptor in an inactive state, effectively suppressing the signaling cascade initiated by the H1 R. This primary molecular action leads to the interruption of histamine-mediated sensory nerve stimulation and minimizing histamine-induced increase in vascular permeability, resulting in reduced fluid extravasation into tissues.


Influencing Late-Stage Inflammatory Cell Recruitment

Beyond direct receptor blockade, Levocetirizine influences the pathways of late-phase inflammation. This mechanism involves suppressing the chemotaxis (migration) of inflammatory cells, such as eosinophils, into tissues. It also reduces the expression of cell adhesion molecules (like VCAM-1) on the endothelial surfaces. By limiting the movement and accumulation of these cells, the drug engages mechanisms that limit cellular infiltration in inflammatory processes.


Mechanism Constraint on Diagnostic Skin Reactivity

A functional consequence of the drug’s high-affinity H1 R mechanism is the complete local suppression of the histamine-induced wheal-and-flare reaction in the skin. This powerful, localized physiological blockade renders diagnostic procedures like allergy skin tests functionally irrelevant while the drug is present, requiring a period of discontinuation to allow restoration of baseline H1 R function.

Dosage and Administration Information

How to Use Analerg

Analerg (levocetirizine dihydrochloride) is approved for oral administration, available either as a film-coated tablet or as an oral solution. The tablets are supplied in a 5 mg strength and are scored, which allows for the administration of a 2.5 mg dose. The liquid oral solution is concentrated at 2.5 mg per 5 mL, enabling accurate volumetric measurement for specific dosing.

The standard regimen for adults and adolescents (12 years of age and older) is 5 mg taken once daily, typically administered in the evening. This medication can be consumed without regard to food intake. The maximum daily dose for this population is 5 mg and should not be exceeded.

Usage for pediatric populations involves specific dosing based on age. Children aged 6 to 11 years receive a daily dose of 2.5 mg in the evening, while the dose for children 6 months to 5 years is 1.25 mg of the oral solution, also taken once daily.

Dose modification is required for adults with impaired kidney function. The dosing interval or dose is adjusted based on the degree of renal impairment (mild, moderate, or severe) to prevent excessive accumulation. For example, patients with moderate impairment take 2.5 mg once every other day. Furthermore, the medicine is contraindicated for use in patients with end-stage renal disease and in children (6 months to 11 years) who have any form of renal impairment.

Recent Clinical Evidence

Recent Clinical Evidence


Biological Activity Research

Laboratory research has investigated the drug's proposed biological activity. Research has explored the time course of observed changes in symptoms in participants from clinical trials.

Clinical Efficacy Research

Clinical studies investigated the impact of a specific intake condition on measured pharmacokinetic outcomes, such as drug absorption. Randomized controlled trials (RCTs) form the core evidence base for the drug's clinical use.

One RCT on a specific patient group reported an observed change in chronic pain over the study period, focusing on participants with moderate-to-severe symptoms. This result contributed to the overall evidence base for this condition.

  • Clinical trials evaluated whether the drug was associated with a change in the severity of inflammation and whether it correlated with patient mobility.
  • Research examined the time required for a change in symptoms to be noted in study subjects.
  • Studies have explored comparisons between this drug and existing treatments.

Safety and Tolerability Data

Post-market surveillance studies examined the participant outcomes who had pre-existing heart problems. Research focused on the frequency and severity of adverse events reported in clinical trials. The severity of these events was characterized in the study reports, which helps in understanding the drug's tolerability profile. Research examined whether discontinuation rates due to adverse events differed between the treatment group and the placebo group.

Frequently Asked Questions (FAQ)

Common questions about Analerg (FAQ)


Q: How is Analerg described as working compared to older allergy medicines?

Analerg is classified as a second-generation antihistamine. Regulatory documents state that unlike older, first-generation antihistamines, medicines in this class are less likely to cross the blood-brain barrier. This difference in action is what reduces the potential for drowsiness compared to some other allergy medications.


Q: What types of allergic symptoms is Analerg typically used to address?

According to the official product information, Analerg is indicated for the relief of symptoms associated with allergic rhinitis. These commonly include a runny nose, sneezing, and the itching or tearing of the eyes caused by allergies. It is also indicated for the treatment of symptoms of chronic hives (urticaria), such as itching and rash.


Q: What is the difference between Analerg and common over-the-counter allergy pills?

Analerg (Levocetirizine) is categorized as a second-generation H1-receptor antagonist. This pharmacological classification identifies it as a highly targeted agent that works selectively on the peripheral receptors that trigger allergic reactions. This selective mechanism is associated with its role as a selective antihistamine and a reduced risk of certain central nervous system effects compared to some older allergy medications.


Q: Are there concerns about the long-term safety of taking Analerg daily?

The most notable documented pattern related to long-term use concerns potential withdrawal symptoms upon cessation. Official product information notes that after taking the medicine regularly for several months or years, an emergence of severe itching (pruritus) may occur shortly after stopping the medication.


Q: Can Analerg be used alongside other over-the-counter cold and flu products?

Analerg is officially noted to cause drowsiness, sleepiness, or difficulty concentrating. Regulatory warnings advise caution when using it alongside other over-the-counter cold or flu medications that may also contain central nervous system (CNS) depressants. Combining these types of medications carries a risk of increased sedation and greater impairment of mental alertness.


Q: How long does it usually take to feel the full effects of Analerg after the first dose?

Clinical pharmacology data indicates that Analerg is rapidly absorbed by the body. Studies show that peak concentrations of the active substance in the blood are typically achieved in adults in under one hour (approximately 0.9 hour) after taking the oral dose.


Q: Does the therapeutic effect of Analerg last for 12 hours or a full 24 hours?

Analerg is approved for a once-daily dosing regimen. This usage instruction confirms that the medication is intended to provide symptom relief for a full 24-hour period before the next dose is due.


Q: Is Analerg intended for use only during allergy season or can it be taken year-round?

Regulatory documents indicate that Analerg is approved for the relief of symptoms associated with both seasonal allergic rhinitis and perennial allergic rhinitis. This confirms its use is appropriate for managing both temporary, seasonal symptoms and year-round (perennial) allergy symptoms, as indicated in the regulatory scope.


Q: Why do some users suggest taking Analerg in the evening before bed?

The official product information often specifies administration once daily in the evening. This timing is generally suggested to align with the medication’s potential common side effect of sleepiness or drowsiness, helping to manage that effect during waking hours.


Q: Are there specific contraindications for taking Analerg related to kidney or liver health?

The medicine is explicitly contraindicated (must not be used) in patients with end-stage renal disease (severe kidney impairment). Official product information does not require any dose adjustment for patients who have only hepatic (liver) impairment.


Q: What is the typical onset time mentioned in the clinical studies for Analerg?

Clinical studies indicate that Analerg is quickly absorbed into the bloodstream. The time required to reach the peak blood concentration of the drug is approximately 0.9 hours in adults, suggesting a rapid onset of activity.


Q: Does Analerg carry a risk of causing a paradoxical reaction like increased nervousness or agitation?

Official adverse event reporting has categorized psychiatric adverse reactions such as agitation as uncommon (reported in 0.1% to 1% of patients). Other reactions categorized as nervousness have also been noted in official reports.


Q: Are there any known side effects of Analerg that affect vision, such as blurry eyes?

Although not common, post-marketing surveillance reports have noted the occurrence of visual disturbances, including blurred vision. These effects are generally categorized as very rare adverse reactions.


Q: Can Analerg affect a person's ability to drive or operate machinery?

Yes. The official label includes a warning cautioning against operating hazardous machinery or driving until the individual is aware of how the medication affects them. This is because Analerg may cause somnolence, fatigue, or other impairment of central nervous system function.


Q: Does Analerg interact with commonly used acid reflux or heartburn medications?

Co-administration studies were conducted with the acid-reducing medication Cimetidine. These studies officially showed that there was no clinically significant change in the overall exposure (pharmacokinetic interaction) to Analerg when taken alongside Cimetidine.


Q: What is the half-life of Analerg as described in the pharmacokinetics data?

Pharmacokinetic studies summarized in regulatory documents provide information on how the body processes the drug. For adults, the estimated elimination half-life (the time required for the amount of drug in the body to be reduced by half) is approximately 7.5 hours.


Q: Is there any evidence that Analerg can cause weight changes?

Official adverse event reporting has noted weight gain in post-marketing reports. However, the exact frequency of this adverse reaction in the general population is currently not known.


Q: How does Analerg compare to the active ingredient in Claritin (loratadine) in terms of sedation?

Analerg (Levocetirizine) is a second-generation antihistamine like Loratadine. However, regulatory safety comparisons have suggested that Analerg may be associated with a higher potential for sleepiness (somnolence or drowsiness) compared to Loratadine.


Q: Does the official documentation mention any warnings about cardiac issues or heart rhythm while using Analerg?

Official adverse event reports have noted rare cardiac adverse effects. These have included reports of tachycardia (fast heart rate). The occurrence of palpitations (a fluttering or pounding heart) has also been noted in post-marketing surveillance reports.


Q: Can Analerg be used by people who have a history of glaucoma?

Official warnings advise caution for the use of Analerg in patients with narrow-angle glaucoma. This precaution is noted due to the medication's potential for anticholinergic effects, which could exacerbate the condition.


Q: Is the active ingredient in Analerg found in any other allergy products?

The active ingredient, Levocetirizine, is available under other brand names. Official documentation also warns patients about known hypersensitivity to the related compound, Cetirizine, which is the precursor drug of Levocetirizine.


Q: Are there any restrictions on combining Analerg with decongestants?

While no direct drug-drug interaction is officially noted with common decongestants like phenylephrine, regulatory information suggests caution may be warranted due to the potential for additive cardiovascular or CNS effects associated with sympathomimetic agents (decongestant components).


Q: Why do people sometimes take Analerg even when they don't have active allergy symptoms?

Official summaries of use state that Analerg is indicated both to prevent and to treat allergy symptoms. It works by blocking histamine, a substance released by the body during an allergic reaction, making it useful as a prophylactic treatment.


Q: Is Analerg generally safe for use in individuals with high blood pressure?

Official label information does not list high blood pressure as a contraindication. However, some post-marketing adverse effect reports have noted rare instances of high blood pressure (hypertension) occurring as a side effect.


Q: Can Analerg be taken by someone who has an enlarged prostate?

Official warnings advise caution for the use of Analerg in patients who have predisposing factors for urinary retention, such as prostatic hyperplasia (enlarged prostate). The regulatory label states that the medicine should be discontinued if urinary retention is observed.

How should Analerg be stored and disposed of?

How to Store and Dispose of Analerg

Official regulatory guidelines define strict conditions for the storage and disposal of this medicine, referred to here as Analerg.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, 15 C to 30 C (59 F to 86 F).
Protection Keep from freezing, and protect from heat, moisture, and direct light.
Packaging Must be dispensed in a tight, light-resistant container.
Child Safety WARNING: Keep this and all medications out of the reach of children. The container requires a child-resistant closure.

Disposal Instructions

To prevent environmental contamination, do not release Analerg to the sewer or household waste. Unused or expired medicine must be disposed of as regulated pharmaceutical waste. Consult a healthcare professional or local authorized collection site for instructions on how to properly dispose of any medicine that is no longer needed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Analerg found in:

A-Z Index: